UBS AM’s Verve Therapeutics VERV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $2.06M | Buy |
183,610
+50,044
| +37% | +$562K | ﹤0.01% | 2124 |
|
|
2025
Q1 | $610K | Buy |
133,566
+13,748
| +11% | +$62.8K | ﹤0.01% | 2455 |
|
|
2024
Q4 | $676K | Buy |
119,818
+4,777
| +4% | +$26.9K | ﹤0.01% | 2492 |
|
|
2024
Q3 | $557K | Buy |
115,041
+6,595
| +6% | +$31.9K | ﹤0.01% | 2611 |
|
|
2024
Q2 | $529K | Buy |
108,446
+61,854
| +133% | +$302K | ﹤0.01% | 2613 |
|
|
2024
Q1 | $619K | Hold |
46,592
| – | – | ﹤0.01% | 2221 |
|
|
2023
Q4 | $649K | Hold |
46,592
| – | – | ﹤0.01% | 2228 |
|
|
2023
Q3 | $618K | Buy |
46,592
+24,077
| +107% | +$319K | ﹤0.01% | 2200 |
|
|
2023
Q2 | $325K | Hold |
22,515
| – | – | ﹤0.01% | 2452 |
|
|
2023
Q1 | $325K | Buy |
22,515
+1,160
| +5% | +$16.7K | ﹤0.01% | 2452 |
|
|
2022
Q4 | $413K | Sell |
21,355
-6,147
| -22% | -$119K | ﹤0.01% | 2247 |
|
|
2022
Q3 | $945K | Buy |
27,502
+12,502
| +83% | +$429K | ﹤0.01% | 1999 |
|
|
2022
Q2 | $229K | Buy |
+15,000
| New | +$229K | ﹤0.01% | 2550 |
|
|
2022
Q1 | – | Sell |
-8,100
| Closed | -$299K | – | 2823 |
|
|
2021
Q4 | $299K | Buy |
+8,100
| New | +$299K | ﹤0.01% | 2677 |
|